Table 1 Characteristics of study patients
Variable | All patients (n = 215) | Development cohort | Validation cohort | P value* | ||||
|---|---|---|---|---|---|---|---|---|
Patients without PHLF (n = 133) | Patients with PHLF (n = 17) | P value | Patients without PHLF (n = 59) | Patients with PHLF (n = 6) | P value | |||
Age (years) | 54 ± 11 | 55 ± 10 | 52 ± 11 | 0.528 | 52 ± 9 | 54 ± 11 | 0.366 | 0.556 |
Numbers of male patients (%) | 179 (83.2) | 119 (89.5) | 15 (88.2) | 0.876 | 51 (86.4) | 5 (83.3) | 0.834 | 0.504 |
Body mass index (kg/m2) | 23.0 ± 3.2 | 23.2 ± 3.3 | 21.5 ± 2.3 | 0.060 | 22.7 ± 3.0 | 22.3 ± 2.7 | 0.320 | 0.679 |
Serum biomarker levels | ||||||||
Platelet count (109/L) | 137 | 143 | 147 | 0.921 | 138 | 141 | 0.098 | 0.053 |
TB (μ mol/L) | 14.3 | 14.3 | 15.1 | 0.785 | 14.2 | 14.7 | 0.112 | 0.685 |
AST (U/L) | 34 | 34 | 41 | 0.232 | 33 | 40 | 0.304 | 0.656 |
ALT (U/L) | 33 | 33 | 34 | 0.787 | 32 | 45 | 0.145 | 0.966 |
Albumin (g/L) | 42.2 | 42.2 | 38.5 | 0.170 | 42.7 | 39.2 | 0.169 | 0.521 |
INR | 1.03 | 1.03 | 1.05 | 0.171 | 1.06 | 1.04 | 0.765 | 0.072 |
Histological inflammation grade | ||||||||
G0 | 20 | 14 | 3 | 0.547 | 3 | 0 | 0.910 | 0.415 |
G1 | 55 | 35 | 2 | 16 | 2 | |||
G2 | 87 | 51 | 7 | 26 | 3 | |||
G3 | 53 | 33 | 5 | 14 | 1 | |||
Fibrosis stage | ||||||||
S0 | 21 | 13 | 1 | 0.567 | 7 | 0 | 0.670 | 0.757 |
S1 | 10 | 6 | 0 | 3 | 1 | |||
S2 | 32 | 21 | 1 | 9 | 1 | |||
S3 | 52 | 30 | 4 | 17 | 1 | |||
S4 | 100 | 63 | 11 | 23 | 3 | |||
Tumor size > 5 cm (%) | 91 (42.3) | 47 (35.3) | 9 (52.9) | 0.158 | 31 (52.5) | 4 (66.7) | 0.508 | 0.024 |
Operative factors | ||||||||
Hilar occlusion (min) | 14 | 14 | 15 | 0.378 | 13 | 14 | 0.102 | 0.067 |
Operative time (min) | 256 | 256 | 254 | 0.138 | 254 | 251 | 0.645 | 0.122 |
Blood loss (mL) | 300 | 300 | 400 | 0.059 | 200 | 300 | 0.496 | 0.061 |